China Pharma Holdings, Inc. — Q1 2017 Form 10-Q
Business context and period. The company manufactures and markets generic and branded pharmaceutical and biochemical products, primarily in China through its subsidiary Helpson. This unaudited report covers the three months ended March 31, 2017, compared with Q1 2016; balance-sheet figures are compared with December 31, 2016.
Key financial results
| Metric | Q1 2017 | Q1 2016 / prior date |
|---|---|---|
| Revenue | $3.285 million | $3.640 million |
| Gross profit / margin | $0.718 million / 21.9% | $0.641 million / 17.6% |
| Operating loss | $0.803 million | $1.321 million |
| Net loss | $0.967 million | $1.553 million |
| Loss per share, basic and diluted | $0.02 | $0.04 |
| Cash provided by operating activities | $0.010 million | $1.303 million |
| Cash and cash equivalents | $2.524 million | $2.666 million at Dec. 31, 2016 |
| Total assets / total liabilities | $78.143 million / $19.721 million | $78.520 million / $19.611 million at Dec. 31, 2016 |
Cost of revenue was $2.567 million, or 78% of revenue, versus $3.000 million, or 82%, a year earlier. Operating expenses were $1.520 million, including $0.360 million of bad-debt expense. The company recorded $0.030 million of income-tax expense. Comprehensive loss was $0.487 million, including $0.480 million of foreign-currency translation income.
Liquidity, debt, and balance-sheet considerations
- Current assets were $17.461 million and current liabilities were $10.540 million at quarter-end. Cash was $2.524 million; an additional $1.719 million was restricted to secure banker’s acceptance notes, with a corresponding $1.719 million notes-payable liability.
- The construction loan facility totaled $10.014 million outstanding, including $1.440 million current and $8.574 million non-current. The loan bears a stated current rate of 5.39%; approximately $1.306 million of principal was due in July 2017. The company paid approximately $0.145 million of principal during Q1.
- A board member’s $1.355 million advance remains payable and bears 1% annual interest. Total liabilities also include $0.607 million of deferred tax liability.
- Net trade receivables were $3.704 million, net of a $16.161 million allowance. Receivables over 90 days were approximately $3.5 million; 72.7% of gross receivables were over 720 days old. The filing says normal customer terms are 90 days but notes that delayed payment by hospitals and distributors is common in the PRC.
- Inventory was $6.986 million, net of a $5.901 million obsolescence reserve. Advances for purchases of intangible assets were $35.772 million.
Material changes and management commentary
- Revenue fell 9.8%, which management primarily attributed to Chinese Spring Festival effects on purchasing and logistics. Anti-viral/infection and respiratory sales declined 14% to $2.17 million, mainly due to lower Cefaclor Dispersible Tablet sales following CFDA market rectification. “Other” sales rose 46% to $0.45 million, mainly on Vitamin B6.
- Gross margin improved to 21.9%, which management attributed to improved margins on major products. Selling expense declined to $0.718 million from $0.969 million; G&A rose to $0.417 million from $0.319 million, primarily due to listing-maintenance payments. R&D declined to $0.026 million from $0.093 million.
- Net loss narrowed mainly because bad-debt expense declined. Despite the smaller loss, operating cash flow fell sharply to $0.010 million from $1.303 million.
- The PRC tax rate increased from 15% in 2016 to 25% in 2017. The company decided not to renew its National High-Tech Enterprise status; management expects a 25% rate in 2017 and thereafter.
- Management believes operating cash flow will cover working capital and anticipated capital expenditure for the next 12 months, but cautions that changed circumstances could require additional financing or spending reductions. It gives no specific earnings or revenue forecast.
Outlook, risks, contingencies, and unusual items
- Generic-drug consistency evaluations and evolving CFDA requirements apply to many marketed and pipeline products. Management says compliance will be a core near-term task; revisions have delayed approvals, increased required work and costs, and the pipeline had no further development in Q1.
- The company is obligated to pay laboratories and other providers approximately $4.4 million over about four years, subject to completion of contract milestones for formula approvals. In 2016, it recorded a $3.962 million impairment on advances to five laboratories; no formula production approvals were obtained in Q1 2017.
- All revenue is denominated in RMB. Currency conversion and remittances out of China are subject to government approval; management says cash held by Helpson is considered indefinitely reinvested and may not be available to the parent or shareholders.
- Customer concentration is material to receivables: two customers represented 46.2% and 15% of accounts receivable. Four suppliers represented 23.7%, 17.3%, 13.6%, and 12.7% of raw-material purchases.
- PRC tax-loss carryforwards were approximately $52.2 million and begin expiring in 2018; the company maintained a $21.963 million valuation allowance against deferred tax assets. The filing also cites PRC political, regulatory, economic, banking, and foreign-exchange risks.
- Management concluded disclosure controls and procedures were ineffective at March 31, 2017, citing insufficient personnel knowledgeable in U.S. GAAP financial reporting. No material change in internal control over financial reporting was identified during the quarter.
Important facts for investors to verify
- Whether cash generation improves and the July 2017 construction-loan principal installment and later scheduled maturities are met.
- Recoverability and aging of receivables, including the adequacy of the $16.161 million allowance and exposure to the two large receivable customers.
- Progress and potential costs of generic-drug consistency evaluations, CFDA approvals, and the $4.4 million milestone-based commitments.
- Whether the company can sustain the improved gross margin while revenue remains pressured, and the effect of the 25% tax rate.
- Remediation of ineffective disclosure controls and the practical availability of PRC-held cash to the U.S. parent.